AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25349310 — intervention group
Group type: EXPERIMENTAL
Intervention: FASD (Fetal Alcohol Spectrum Disorders)
Number of subjects: 70
Study 25349310 — intervention group
Group type: COMPARATOR
Intervention: FAS
Number of subjects: 70
Study 25349310 — intervention group
Group type: COMPARATOR
Intervention: PFAS
Number of subjects: 70
Study 25349310 — intervention group
Group type: COMPARATOR
Intervention: Total FASD
Number of subjects: 70
Study 22386229 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative enzyme-linked immunoassay (EIA)
Number of subjects: 30
Study 22386229 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocket immune-electrophoresis (RIE)
Number of subjects: 30
Study 22386229 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromatographic immunoassay (CIA)
Number of subjects: 30
Study 22386229 — intervention group
Group type: COMPARATOR
Intervention: Self-reported condom failures
Number of subjects: 30
Study 20441129 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental focus that fits chronic self-regulatory focus
Number of subjects: 0
Study 20441129 — intervention group
Group type: COMPARATOR
Intervention: Nonfit conditions
Number of subjects: 0
Study 17592653 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interviews
Number of subjects: 4000
Study 17592653 — intervention group
Group type: COMPARATOR
Intervention: Mailed questionnaires
Number of subjects: 4000
Study 16350679 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined supplementation of fish oil (600 mg) with garlic pearls (500 mg) per day for 60 days
Number of subjects: 16
Study 16350679 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 16
Study 12486987 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer and paper reporting methods
Number of subjects: 42
Study 9794052 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional restoration program for patients with moderate low back pain.
Number of subjects: 160
Study 9794052 — intervention group
Group type: COMPARATOR
Intervention: One-footed postural control measurement.
Number of subjects: 160
Study 9794052 — intervention group
Group type: COMPARATOR
Intervention: One-footed postural stability measurement.
Number of subjects: 160
Study 7667128 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable thermometer
Number of subjects: 0
Study 7667128 — intervention group
Group type: COMPARATOR
Intervention: Mercury thermometer
Number of subjects: 0
Study 2570701 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine 10 mg
Number of subjects: 20
Study 2570701 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine diHCl 10 mg
Number of subjects: 20
Study 2570701 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 1183219 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate ointment
Number of subjects: 29
Study 1183219 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone acetonide ointment
Number of subjects: 29
Study 31271308 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 18
Study 31271308 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional plyometric training)
Number of subjects: 18
Study 28957407 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiconductor laser irradiation at 1W for 20 seconds
Number of subjects: 60
Study 28957407 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic rinsing for 60 seconds
Number of subjects: 60
Study 28957407 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment prior to RCT)
Number of subjects: 60
Study 25986641 — intervention group
Group type: EXPERIMENTAL
Intervention: Health consultation involving a self-help manual, monthly prompts, and spirometry
Number of subjects: 550
Study 25986641 — intervention group
Group type: COMPARATOR
Intervention: Spirometry followed by usual care (Control)
Number of subjects: 550
Study 23892341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 250 mg (steroid group)
Number of subjects: 90
Study 23892341 — intervention group
Group type: COMPARATOR
Intervention: Standard PVI without IV hydrocortisone (nonsteroid group)
Number of subjects: 90
Study 21894706 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupotomology
Number of subjects: 184
Study 21894706 — intervention group
Group type: COMPARATOR
Intervention: Operation
Number of subjects: 184
Study 19254601 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based exercise program
Number of subjects: 82
Study 19254601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pool-based exercise program
Number of subjects: 82
Study 19254601 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 82
Study 17197377 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate substitution with lopinavir/ritonavir 400/100 mg bid
Number of subjects: 849
Study 10232529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraearly angiographic vasospasm (UEAV)
Number of subjects: 296
Study 10232529 — intervention group
Group type: COMPARATOR
Intervention: Early surgery (within 48 h of hemorrhage onset)
Number of subjects: 296
Study 10232529 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with UEAV who did not undergo early surgery
Number of subjects: 296
Study 8916803 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin + Quinine (AQ)
Number of subjects: 161
Study 8916803 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin + Doxycycline (AD)
Number of subjects: 161
Study 8916803 — intervention group
Group type: COMPARATOR
Intervention: Quinine (Q)
Number of subjects: 161
Study 1926985 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (10 mg bid)
Number of subjects: 11
Study 6126170 — intervention group
Group type: EXPERIMENTAL
Intervention: THIP (10 to 25 mg single dose; 20 to 120 mg daily for four weeks)
Number of subjects: 18
Study 6126170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30890001 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding enteral feeding (NPO) during RBC transfusion
Number of subjects: 112
Study 30890001 — intervention group
Group type: COMPARATOR
Intervention: Continuance of feeding (FED) during RBC transfusion
Number of subjects: 112
Study 30890001 — intervention group
Group type: EXPERIMENTAL
Intervention: NPO and FED groups
Number of subjects: 112
Study 31515185 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive hemicraniectomy (DHC)
Number of subjects: 86
Study 31515185 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 86
Study 31515185 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 86
Study 29341471 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal tolerated dose of valsartan (titrated up to 320 mg/day, n=333)
Number of subjects: 495
Study 29341471 — intervention group
Group type: COMPARATOR
Intervention: Low-dose valsartan (80 mg/day, n=162)
Number of subjects: 495
Study 29341471 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal tolerated dose of valsartan (titrated up to 320 mg/day)
Number of subjects: 495
Study 29341471 — intervention group
Group type: COMPARATOR
Intervention: Low-dose valsartan (80 mg/day)
Number of subjects: 495
Study 25952055 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based self-management rehabilitation programme
Number of subjects: 128
Study 23760035 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal and bitemporal electrode placements during ECT
Number of subjects: 40
Study 23760035 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure duration during ECT
Number of subjects: 40
Study 22174029 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (Atx) 80 mg daily for 12 weeks
Number of subjects: 64
Study 22174029 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 64
Study 22174029 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (Atx)
Number of subjects: 64
Study 21143048 — intervention group
Group type: EXPERIMENTAL
Intervention: Australian Medical Sheepskin
Number of subjects: 1281
Study 21143048 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1281
Study 17697477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 71
Study 17697477 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 71
Study 15616046 — intervention group
Group type: EXPERIMENTAL
Intervention: J-tip directed caudad (Group 1)
Number of subjects: 295
Study 15616046 — intervention group
Group type: COMPARATOR
Intervention: J-tip directed cephalad (Group 2)
Number of subjects: 295
Study 12472369 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic agents
Number of subjects: 0
Study 12472369 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 0
Study 12472369 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 12472369 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic drugs
Number of subjects: 0
Study 12472369 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 0
Study 10084468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium plus Albuterol
Number of subjects: 1067
Study 10084468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 1067
Study 10084468 — intervention group
Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 1067
Study 10084468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium plus Albuterol and Ipratropium
Number of subjects: 1067
Study 7604808 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute alcohol consumption (70 g of ethanol diluted to 20% with lemonade)
Number of subjects: 10
Study 7604808 — intervention group
Group type: COMPARATOR
Intervention: Reference (lemonade alone)
Number of subjects: 10
Study 7604808 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute alcohol consumption
Number of subjects: 10
Study 7604808 — intervention group
Group type: COMPARATOR
Intervention: Reference
Number of subjects: 10
Study 2195934 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg three times per day for 14 days
Number of subjects: 46
Study 2195934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 30704412 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy load resistance training (HRT)
Number of subjects: 36
Study 30704412 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate load resistance training (MRT)
Number of subjects: 36
Study 30704412 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 36
Study 29136270 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Seconds to Survival (60S) video game; played at least three times over 13 weeks.
Number of subjects: 47
Study 29136270 — intervention group
Group type: COMPARATOR
Intervention: Control group (no disaster training during the study).
Number of subjects: 47
Study 26802969 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromechanical gait trainer (GT) combined with conventional physiotherapy
Number of subjects: 106
Study 26802969 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy alone
Number of subjects: 106
Study 24422622 — intervention group
Group type: EXPERIMENTAL
Intervention: High level model of care
Number of subjects: 0
Study 24422622 — intervention group
Group type: COMPARATOR
Intervention: Low level model of care
Number of subjects: 0
Study 22766970 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO(2) laser treatments (3 monthly sessions, MedArt 610; 12-14 W, 48-56 mJ/pulse, 13% density)
Number of subjects: 13
Study 22766970 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 13
Study 20362975 — intervention group
Group type: EXPERIMENTAL
Intervention: ERP+DCS
Number of subjects: 22
Study 20362975 — intervention group
Group type: COMPARATOR
Intervention: ERP+placebo
Number of subjects: 22
Study 17110643 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 220
Study 17110643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 15507534 — intervention group
Group type: EXPERIMENTAL
Intervention: [3H]triolein
Number of subjects: 24
Study 15507534 — intervention group
Group type: EXPERIMENTAL
Intervention: [14C]triolein
Number of subjects: 24
Study 15507534 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 24
Study 15507534 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 24
Study 15507534 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual cycle factors
Number of subjects: 24
Study 12016098 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (plasma level of 9-11 mg/L) for 4 weeks
Number of subjects: 25
Study 10198737 — intervention group
Group type: EXPERIMENTAL
Intervention: NC100100
Number of subjects: 203
Study 10198737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent harmonic imaging with NC100100 at 0.03 microliter particles/kg body weight
Number of subjects: 203
Study 8778133 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear description profiles
Number of subjects: 5
Study 8778133 — intervention group
Group type: COMPARATOR
Intervention: Unclear description profiles
Number of subjects: 5
Study 8778133 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotic simulation profiles
Number of subjects: 5
Study 8778133 — intervention group
Group type: COMPARATOR
Intervention: Psychotic simulation profiles
Number of subjects: 5
Study 8778133 — intervention group
Group type: EXPERIMENTAL
Intervention: Authentic profiles
Number of subjects: 5
Study 8778133 — intervention group
Group type: COMPARATOR
Intervention: Simulated profiles
Number of subjects: 5
Study 2171115 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive electrodes
Number of subjects: 26
Study 2171115 — intervention group
Group type: COMPARATOR
Intervention: Ordinary electrodes
Number of subjects: 26
Study 346628 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (cat pelt extract)
Number of subjects: 10
Study 346628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31362784 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (8 mg per day)
Number of subjects: 65
Study 31362784 — intervention group
Group type: COMPARATOR
Intervention: Bupropion (300 mg per day)
Number of subjects: 65
Study 27632069 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (CS)
Number of subjects: 98
Study 27632069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Number of subjects: 98
Study 27632069 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer solution (LR; placebo)
Number of subjects: 98
Study 27632069 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotic use
Number of subjects: 98
Study 27632069 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs) use
Number of subjects: 98
Study 26502867 — intervention group
Group type: EXPERIMENTAL
Intervention: Casperome® 500 mg/day
Number of subjects: 32
Study 26502867 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment
Number of subjects: 32
Study 23810644 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate, 300 mg daily
Number of subjects: 170
Study 23810644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 21543963 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 g total dietary fiber per day from psyllium
Number of subjects: 189
Study 21543963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 21543963 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady dose segment (all fiber sources)
Number of subjects: 189
Study 21543963 — intervention group
Group type: EXPERIMENTAL
Intervention: Total symptom severity and emotional upset
Number of subjects: 189
Study 18793657 — intervention group
Group type: EXPERIMENTAL
Intervention: Response procedure using drawings (crossing out face drawings)
Number of subjects: 67
Study 18793657 — intervention group
Group type: COMPARATOR
Intervention: Response procedure using words (circling corresponding words)
Number of subjects: 67
Study 17456571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (Cb2) 0.5 mg/d
Number of subjects: 69
Study 17456571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 15628041 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (2 x 50 microg/day)
Number of subjects: 24
Study 15628041 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide (4 x 40 microg/day)
Number of subjects: 24
Study 11346842 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe TBI group
Number of subjects: 51
Study 11346842 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild TBI group
Number of subjects: 51
Study 11346842 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-TBI trauma)
Number of subjects: 51
Study 9562228 — intervention group
Group type: EXPERIMENTAL
Intervention: Acesal (rapidly dispersing acetylsalicylic acid)
Number of subjects: 24
Study 9562228 — intervention group
Group type: EXPERIMENTAL
Intervention: Acesal Extra (rapidly dispersing acetylsalicylic acid)
Number of subjects: 24
Study 9562228 — intervention group
Group type: EXPERIMENTAL
Intervention: Micristin (microencapsuled acetylsalicylic acid)
Number of subjects: 24
Study 7881507 — intervention group
Group type: COMPARATOR
Intervention: State hospital delivery
Number of subjects: 221
Study 7881507 — intervention group
Group type: COMPARATOR
Intervention: Private hospital delivery
Number of subjects: 221
Study 7881507 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 221
Study 7881507 — intervention group
Group type: COMPARATOR
Intervention: Caesarean delivery
Number of subjects: 221
Study 3259110 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50
Study 3259110 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone-isoflurane
Number of subjects: 50
Study 31586305 — intervention group
Group type: EXPERIMENTAL
Intervention: Back Propagation Neural Network (BPNN) model
Number of subjects: 13639
Study 31586305 — intervention group
Group type: COMPARATOR
Intervention: Multiple Linear Regression (MLR) model
Number of subjects: 13639
Study 29519777 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT) for 14 weeks (n=117)
Number of subjects: 239
Study 29519777 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n=122)
Number of subjects: 239
Study 29061168 — intervention group
Group type: EXPERIMENTAL
Intervention: Silence is Deadly program
Number of subjects: 8
Study 29061168 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 8
Study 26338889 — intervention group
Group type: EXPERIMENTAL
Intervention: Dal (lentils enriched to 85.1% with (57)Fe, 8 mg native (57)Fe)
Number of subjects: 19
Study 26338889 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate (7 mg FeSO4 plus 1 mg (58)Fe)
Number of subjects: 19
Study 26338889 — intervention group
Group type: EXPERIMENTAL
Intervention: Dal (for anemic women)
Number of subjects: 19
Study 26338889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (for anemic women)
Number of subjects: 19
Study 23081872 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital ovulation tests
Number of subjects: 210
Study 20846920 — intervention group
Group type: COMPARATOR
Intervention: AR (CAG)(>24)/(CAG)(>24) genotype category
Number of subjects: 1960
Study 20846920 — intervention group
Group type: COMPARATOR
Intervention: AR (GGC)(17)/(GGC)(14) genotype
Number of subjects: 1960
Study 18301184 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Performance Simulator (HPS)
Number of subjects: 0
Study 18301184 — intervention group
Group type: COMPARATOR
Intervention: Didactic Lecture (LEC)
Number of subjects: 0
Study 17138176 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus powder in Orabase 0.1%
Number of subjects: 10
Study 14744167 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 502
Study 14744167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 11767269 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based prevention program
Number of subjects: 2041
Study 11767269 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2041
Study 9406836 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG (human menopausal gonadotropin)
Number of subjects: 13
Study 9406836 — intervention group
Group type: COMPARATOR
Intervention: recombinant FSH
Number of subjects: 13
Study 8427539 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 or 1000 mg daily (n = 21)
Number of subjects: 77
Study 8427539 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 1500 or 2000 mg daily (n = 56)
Number of subjects: 77
Study 8427539 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with clarithromycin
Number of subjects: 77
Study 8427539 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopped treatment for 7 days or longer
Number of subjects: 77
Study 8427539 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 77
Study 8427539 — intervention group
Group type: COMPARATOR
Intervention: Concomitant AIDS drugs
Number of subjects: 77
Study 3304027 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 51
Study 3304027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 30290775 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel chemotherapy
Number of subjects: 57
Study 27055722 — intervention group
Group type: EXPERIMENTAL
Intervention: Written briefing
Number of subjects: 1690
Study 27055722 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone briefing
Number of subjects: 1690
Study 27055722 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face information
Number of subjects: 1690
Study 27055722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no briefing)
Number of subjects: 1690
Study 24299021 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast treatment for 3 months
Number of subjects: 130
Study 24299021 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 130